B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity

Gene Therapy

Volumn 22, Issue 8, 2015, Pages 675-684

  Wu, M R ^a   Zhang, T ^a   DeMars, L R ^b   Sentman, C L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7H6 SPECIFIC CHIMERIC ANTIGEN RECEPTOR; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 1BETA; MEMBRANE ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; B7 ANTIGEN; B7-H6 ANTIGEN, HUMAN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DISEASE MARKER; FLOW CYTOMETRY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEIOMYOSARCOMA; MEDULLOBLASTOMA; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL LINE; WILD TYPE; ANIMAL; C57BL MOUSE; FEMALE; GENE VECTOR; IMMUNOLOGY; LYMPHOMA; METABOLISM; OVARIAN NEOPLASMS; THERAPEUTIC USE;

MURINAE; MUS;

ANIMALS; B7 ANTIGENS; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; HUMANS; LYMPHOMA; MICE, INBRED C57BL; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; OVARIAN NEOPLASMS; T-LYMPHOCYTES;

EID: 84938738213     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.29     Document Type: Article

References (28)

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95-73.
3. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
4. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177-38.
5. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3: 388-398.
6. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005; 106: 1544-1551.
7. Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007; 67: 5003-5008.
8. Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol 2012; 189: 2290-2299.
9. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274.
10. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190: 1505-1516.
11. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206: 1495-1503.
12. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17: 700-707.
13. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007; 109: 323-330.
14. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343-351.
15. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One 2008; 3: e3377.
16. Barth Jr RJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumorinfiltrating lymphocytes. J Exp Med 1991; 173: 647-658.
17. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-686.
18. Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res 2007; 67: 11029-11036.
19. Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G et al. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 2013; 122: 394-404.
20. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
21. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 1398-1403.
22. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14: 4376-4386.
23. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301-1307.
24. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
25. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-851.
26. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-276.
27. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003; 90: 1178-1186.
28. Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 2008; 180: 72-78.